循环无细胞DNA检测及在肝病中的研究应用
Detection and Application of Circulating-Free Cell DNA in Hepatopathy

作者: 陈恳 , 张弘 :南通大学附属医院消化内科,南通;

关键词: 循环无细胞DNA检测肝病Circulating-Free Cell DNA Detection Hepatopathy

摘要:
循环无细胞DNA是一种无细胞状态的胞外DNA,广泛存在于人体体液中。近年来,对循环无细胞DNA的研究逐渐受到人们的重视,越来越多的研究将循环无细胞DNA与临床疾病的关系联系起来。现将近年来有关循环无细胞DNA检测的研究及循环无细胞DNA在肝病中的研究进展作一综述。
Circulating-free cell DNA (cfDNA) is a class of extrocellular DNA without cellular structure, presenting ex-tensively in human body fluids. Recently, cfDNA has gradully received more attention, and extensive studies have in-dicated the relationship between cfDNA and clinical diseases. Here, we review the researches about detection of cfDNA and the research progress about cfDNA in liver disease in recent years.

文章引用: 陈恳 , 张弘 (2013) 循环无细胞DNA检测及在肝病中的研究应用。 医学诊断, 3, 10-14. doi: 10.12677/MD.2013.31003

参考文献

[1] P. Mandel, P. Metais. Les acides nucleiques du plasma sanguin chez 1’ Homme. Comptes Rendus de l’Académie des Sciences Paris, 1948, 142(3): 241-243.

[2] S. A. Leon, B. Shapiro, D. M. Sklaroff, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Re- search, 1977, 37(3): 646-650.

[3] K. W. Lo, Y. M. D. Lo, S. F. Leung, et al. Analysis of cell-free Epstein-Barr virus-associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clinical Chemistry, 1999, 45(8): 1292-1294.

[4] M. S. Kopreski, F. A. Benko, L. W. Kwak, et al. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clinical Cancer Research, 1999, 5(8): 1961-1965.

[5] 杨波, 吴小华, 孙东霞等. 卵巢上皮性癌患者血清无细胞DNA的检测及临床意义[J]. 肿瘤, 2008, 28(4): 334-337.

[6] R. R Jing, J.-H. Zhu, H.-M. Wang, et al. A sensitive method to quantify human circulating free DNA in blood: Relevance to myocardial infarction screening. Clinical Biochemistry, 2011, 44(13): 1074-1079.

[7] B. G. Wang, H. Y. Huang, Y. C. Chen, et al. Increased plasma DNA integrity in cancer patients. Cancer Research, 2003, 63(14): 3966-3968.

[8] S. Holdenrieder, A. Burges, O. Reich, et al. DNA integrity in plasma and serum of patients with malignant and benign disease. Annals of the New York Academy of Sciences, 2008, 1137: 162- 170.

[9] M. S. Kopreski, F. A. Benko, D. J. Borys, et al. Somatic muta- tion screening: Identification of individuals harboring K-ras mutations with the use of plasma DNA. National Cancer Insti- tute, 2000, 92: 918-923.

[10] Z. M. Shao, J. Wu, Z. Z. Shen, et al. p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clinical Cancer Research, 2001, 7(8): 2222-2227.

[11] R. Von knobloch, A. Hegele, H. Brandt, et al. Serum DNA and urine DNA alterations of urinary transitional cell bladder carci- noma detected by fluorescent microsatellite analysis. Interna- tional Journal of Cancer, 2001, 94(1): 67-72.

[12] C. Goessl, H. Krause, M. Muller, et al. Fluorescent methylation- specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Research, 2000, 60(21): 5941-5945.

[13] I. J. Marin, M. Poljak, K. Seme, et al. Comparative evaluation of three commercial assays for quantitative measurement of hepati- tis B virus DNA in serum samples. Hepatogastroenterology, 2002, 49(47): 1390-1394.

[14] S. K. Ho, T. M. Chan. An overview of assays for serum HBV DNA. Clinical Laboratory, 2000, 46(11-12): 609-614.

[15] J. Saldanha. Validation and standardization of nucleic acid am- plification technology (NAT) assays for the detection of viral contamination of blood and blood products. Journal of Clinical Virology, 2001, 20(1-2): 7-13.

[16] 傅占江, 范丽娜, 王沛等. 枝状DNA 信号放大与纸层析杂交检测方法的建立[J]. 中华微生物学和免疫学杂志, 2002, 22(4): 468-469.

[17] K. J. Livak, S. J. Flood, J. Marmaro, et al. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe sys- tem useful for detecting PCR product and nucleic acid hybridi- zation. PCR Methods and Applications, 1995, 4(6): 357-362.

[18] J. Hayashi, Y. Kawakami, A. Nabeshima, et al. Comparison of HCV RNA levels by branched DNA probe assay and by com- petitive polymerase chain reaction to predict effectiveness of in- terferon treatment for patients with chronic hepatitis C virus. Digestive Diseases and Sciences, 1998, 43(2): 384-391.

[19] M. L. Collins, B. Irvine, D. Tyner, et al. A branched DNA signal amplification assay for quantification of nucleic acid targets be- low 100 molecules/ml. Nucleic Acids Research, 1997, 25(15): 2979-2984.

[20] 罗迪贤, 李凯, 何淑雅等. Alu家族及其生物学意义[J]. 遗传, 2005, 27(2): 284-288.

[21] L. Just, M. Timmer, J. Tinius, et al. Identification of human cells in brain xenografts and in neural co-cultures of rat by in situ hy- bridisation with Alu probe. Journal of Neuroscience Methods, 2003, 126(1): 69-77.

[22] G. J. Nuovo, P. MacConnell. Detection of human papilloma virus DNA in formalin-fixed tissues by in situ hybridization after amplification by polymerase chain reaction. American Journal of Pathology, 1991, 139: 847-854.

[23] 任宁, 钦伦秀, 屠红等. 肝细胞癌病人血浆DNA定量分析及其临床意义[J]. 复旦学报, 2005, 32(2): 134-138.

[24] N. Ren, L. X. Qin, H. Tu, et al. The prognostic value of circu- lating plasma DNA level and its allelic imbalance on chromo- some 8p in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2006, 132(6): 399-407.

[25] N. Ren, Q. H. Ye, L. X. Qin, et al. Circulating DNA level is ne- gatively associated with the long-term survival of hepatocellular carcinoma patients. World Journal of Gastroenterology, 2006, 12(24): 3911-3914.

[26] Y. Tokuhisa, N. Lizuka, I. Sakaida,et al. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. British Journal of Cancer, 2000, 97(10): 1399-1403.

分享
Top